Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. - Oligonucleotide Therapeutics Society

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

AUTHOR

OTS

DATE

January 31, 2020

CATEGORIES

Ago/siRNA/saRNA,Hot Papers,Pre-Clinical Research,Toxicology

SHARE

Post Views: 336

Sutherland JE, Hettinger JL, Chan A, Gilbert J, Warner GL, Davis WP.

Nucleic Acid Ther. 2019 Dec 10.

Related articles